KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Edwards Lifesciences (EW) over the last 3 years, with Q4 2021 value amounting to $7.1 million.

  • Edwards Lifesciences' Amortization of Deferred Charges fell 533.33% to $7.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $28.5 million, marking a year-over-year increase of 106.38%. This contributed to the annual value of $28.5 million for FY2021, which is 106.38% up from last year.
  • As of Q4 2021, Edwards Lifesciences' Amortization of Deferred Charges stood at $7.1 million, which was down 533.33% from $7.1 million recorded in Q3 2021.
  • Edwards Lifesciences' Amortization of Deferred Charges' 5-year high stood at $7.5 million during Q4 2020, with a 5-year trough of $5.7 million in Q1 2019.
  • In the last 3 years, Edwards Lifesciences' Amortization of Deferred Charges had a median value of $7.0 million in 2019 and averaged $6.8 million.
  • As far as peak fluctuations go, Edwards Lifesciences' Amortization of Deferred Charges surged by 1754.39% in 2020, and later tumbled by 533.33% in 2021.
  • Edwards Lifesciences' Amortization of Deferred Charges (Quarter) stood at $6.6 million in 2019, then rose by 13.64% to $7.5 million in 2020, then decreased by 5.33% to $7.1 million in 2021.
  • Its last three reported values are $7.1 million in Q4 2021, $7.1 million for Q3 2021, and $7.0 million during Q2 2021.